Sec Form 4/A Filing - TYSON TIMOTHY @ Syros Pharmaceuticals, Inc. - 2022-09-16

FORM 4/A Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person TYSON TIMOTHY 2. Issuer Name and Ticker or Trading Symbol Syros Pharmaceuticals, Inc. [ SYRS] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X __ Director _____ 10% Owner _____ Officer (give title below) _____ Other (specify below) (Last) (First) (Middle) 35 CAMBRIDGEPARK DRIVE 3. Date of Earliest Transaction (MM/DD/YY) 09/16/2022 (Street) CAMBRIDGE, MA02140 4. If Amendment, Date Original Filed (MM/DD/YY) 09/19/2022 6. Individual or Joint/Group Filing (Check Applicable Line) __ X __ Form filed by One Reporting Person _____ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock 09/16/2022 A 8,000 A $ 0 8,000 D Common Stock 09/16/2022 A 257 A 8,257 D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Stock Option (right to buy) $ 7.349 09/16/2022 A 12,000 ( 2 ) 09/15/2032 Common Stock 12,000 $ 0 12,000 D Stock Option (right to buy) $ 93.56 09/16/2022 A 2,232 ( 3 ) 11/21/2022 Common Stock 2,232 ( 3 ) 2,232 D Stock Option (right to buy) $ 199.68 09/16/2022 A 1,094 ( 4 ) 05/09/2026 Common Stock 1,094 ( 4 ) 1,094 D Stock Option (right to buy) $ 66.18 09/16/2022 A 3,286 ( 5 ) 05/24/2028 Common Stock 3,286 ( 5 ) 3,286 D Stock Option (right to buy) $ 53.17 09/16/2022 A 2,191 ( 6 ) 08/26/2028 Common Stock 2,191 ( 6 ) 2,191 D Stock Option (right to buy) $ 26.93 09/16/2022 A 2,191 ( 7 ) 08/22/2029 Common Stock 2,191 ( 7 ) 2,191 D Stock Option (right to buy) $ 27.84 09/16/2022 A 2,848 ( 8 ) 08/19/2030 Common Stock 2,848 ( 8 ) 2,848 D Stock Option (right to buy) $ 25.1 09/16/2022 A 3,856 ( 9 ) 08/23/2031 Common Stock 3,856 ( 9 ) 3,856 D Stock Option (right to buy) $ 7.07 09/16/2022 A 3,856 ( 10 ) 08/23/2032 Common Stock 3,856 ( 10 ) 3,856 D

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other TYSON TIMOTHY 35 CAMBRIDGEPARK DRIVE CAMBRIDGE, MA02140 X Signatures /s/ Todd Rosenthal, as attorney-in-fact 04/20/2023 Signature of Reporting Person Date

Explanation of Responses:

( 1 )Acquired pursuant to the merger agreement between the issuer and Tyme Technologies, Inc. ("Tyme") in exchange for 5,865 shares of Tyme common stock having a market value of $0.3086 per share at the close of trading on September 15, 2022, the last trading day immediately preceding the effective time of the merger, but after giving effect to a 1-for-10 reverse stock split by Syros (the "Reverse Split"), with cash paid in lieu of fractional shares. ( 2 )The option becomes exercisable as to 16.66% of the shares underlying the award on the six month anniversary of the date of grant, with the remainder vesting in equal monthly installments until the third anniversary of the date of grant, subject to the reporting person's continued service as a director through each applicable vesting date. Amounts reported in this Form 4 reflect the 1-for-10 reverse stock split effected by the issuer on September 16, 2022. ( 3 )This option is fully vested and replaced an option to purchase 50,058 shares of Tyme common stock at an exercise price of $4.10 per Tyme share that was assumed in the merger, after giving effect to the Reverse Split. ( 4 )This option is fully vested and replaced an option to purchase 25,000 shares of Tyme common stock at an exercise price of $8.75 per Tyme share that was assumed in the merger, after giving effect to the Reverse Split. ( 5 )This option is fully vested and r eplaced an option to purchase 75,000 shares of Tyme common stock at an exercise price of $2.90 per Tyme share that was assumed in the merger, after giving effect to the Reverse Split. ( 6 )This option is fully vested and replaced an option to purchase 50,000 shares of Tyme common stock at an exercise price of $2.33 per Tyme share that was assumed in the merger, after giving effect to the Reverse Split. ( 7 )This option is fully vested and replaced an option to purchase 50,000 shares of Tyme common stock at an exercise price of $1.18 per Tyme share that was assumed in the merger, after giving effect to the Reverse Split. ( 8 )This option is fully vested and replaced an option to purchase 65,000 shares of Tyme common stock at an exercise price of $1.22 per Tyme share that was assumed in the merger, after giving effect to the Reverse Split. ( 9 )This option is fully vested and replaced an option to purchase 88,000 shares of Tyme common stock at an exercise price of $1.10 per Tyme share that was assumed in the merger, after giving effect to the Reverse Split. ( 10 )This option is fully vested and replaced an option to purchase 88,000 shares of Tyme common stock at an exercise price of $0.31 per Tyme share that was assumed in the merger, after giving effect to the Reverse Split.

Remarks: This amendment to the Statement of Changes in Beneficial Ownership of Securities is being filed to correct the inadvertent omission of the Reporting Person's beneficial ownership of certain securities issued in connection with the closing of the merger with Tyme on September 16, 2022.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.